Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Pharmacol Res. 2017 Apr 8;120:258–266. doi: 10.1016/j.phrs.2017.04.003

Table 1. Unfolded protein response-targeted drugs that inhibit cancer development.

Therapeutic drugs Therapeutic effect related to ER stress Reference
GSK2606414, GSK2656157 (Second generation PERK inhibitor) Inhibits PERK and eIF2α phosphorylation, ATF4 translation and CHOP mRNA expression (67, 68)
ONC201 Inhibits eIF2α (114)
Salicylaldimines, 3-methoxy-6-bromosalicylaldehyde Inhibits IRE1α activity (71)
4μ8C Inhibits IRE1α activity (72)
MKC-3946 Inhibits IRE1α activity (73)
STF-083010 Inhibits IRE1α activity (74)
Toyocamycin Inhibits IRE1α activity (75)
N9-(3-(dimethylamino) propyl)-N3,N3,N6,N6-tetramethylacridine-3,6,9-triamine (3,6-DMAD) Inhibits IRE1α activity (76)
Hydroxy-aryl-aldehydes (HAA) Inhibits IRE1α activity (77)
MKC-3946 Inhibits IRE1α activity (73)
STF-083010 Inhibits IRE1α activity (78)
Irestatin Inhibits IRE1α activity (60)
Eeyarestatin I (EerI) ERAD inhibitor (80)
Versipelostatin; Epigallocatechin gallate Inhibition of GRP78 chaperone function compromises ER protein folding (82, 83)
MAb159, PAT-SM6 GRP78 inhibitors (88, 115)